eribulin mesylate (Halaven)
Jump to navigation
Jump to search
Indications
- FDA-approved for treatment of metastatic breast cancer, intended for patients who have already received at least two regimens of chemotherapy for late-stage disease[1]
Contraindications
- not recommended for treatment of metastatic breast cancer[3]
Dosage
injection
Adverse effects
- leukopenia (neutropenia) 82%
- anemia (58%)
- weakness/tiredness (54%)
- alopecia (45%)
- parestheaia (35%)
- nausea (35%)
- constipation (25%)
Mechanism of action
- binds predominantly to a small number of high affinity sites at the plus ends of existing microtubules
- inhibits microtubule dynamics & thus mitosis
- triggers apoptosis of cancer cells following prolonged & irreversible mitotic blockade[2]
More general terms
References
- ↑ 1.0 1.1 FDA News Release: Nov. 15, 2010 FDA approves new treatment option for late-stage breast cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm233863.htm
- ↑ 2.0 2.1 Wikipedia: Eribulin http://en.wikipedia.org/wiki/Eribulin
- ↑ 3.0 3.1 Havalen (eribulin mesylate) injection http://www.halaven.com/patients.aspx